Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements

Summary This study aimed to evaluate the concordance between minimal residual disease (MRD) results obtained by multicolour flow cytometry (MFC) and polymerase chain reaction for fusion gene transcripts (FGTs) in infants with acute lymphoblastic leukaemia (ALL) associated with rearrangement of the KMT2A gene ( KMT2A ‐r). A total of 942 bone marrow (BM) samples from 123 infants were studied for MFC‐MRD and FGT‐MRD. In total, 383 samples (40.7%) were concordantly MRD‐negative. MRD was detected by the two methods in 441 cases (46.8%); 99 samples (10.5%) were only FGT‐MRD‐positive and 19 (2.0%) were only MFC‐MRD‐positive. A final concordance rate of 87.4% was established. Most discordance occurred if residual leukaemia was present at levels close to the sensitivity limits. Neither the type of KMT2A fusion nor a new type of treatment hampering MFC methodology had an influence on the concordance rate. The prognostic value of MFC‐MRD and FGT‐MRD differed. MFC‐MRD was able to identify a rapid response at early time‐points, whereas FGT‐MRD was a reliable relapse predictor at later treatment stages. Additionally, the most precise risk definition was obtained when combining the two methods. Because of the high comparability in results, these two rather simple and inexpensive approaches could be good options of high clinical value.